

<https://helda.helsinki.fi>

Zinc for preventing and treating the common cold : protocol

Hemilä, Harri Olavi

2017-09-26

Hemilä , H O & Chalker , E 2017 , ' Zinc for preventing and treating the common cold : protocol ' , Cochrane database of systematic reviews , no. CD012808 . <https://doi.org/10.1002/14651858.CD012808>

<http://hdl.handle.net/10138/228207>

<https://doi.org/10.1002/14651858.CD012808>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



Cochrane
Library

Cochrane Database of Systematic Reviews

Zinc for preventing and treating the common cold (Protocol)

Hemilä H, Chalker E

Hemilä H, Chalker E.

Zinc for preventing and treating the common cold.

Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD012808.

DOI: 10.1002/14651858.CD012808.

www.cochranelibrary.com

Zinc for preventing and treating the common cold (Protocol)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
BACKGROUND	1
OBJECTIVES	2
METHODS	2
ACKNOWLEDGEMENTS	5
REFERENCES	6
APPENDICES	8
CONTRIBUTIONS OF AUTHORS	8
DECLARATIONS OF INTEREST	8
SOURCES OF SUPPORT	8

Zinc for preventing and treating the common cold

Harri Hemilä¹, Elizabeth Chalker²

¹Department of Public Health, POB 20, University of Helsinki, Helsinki, Finland. ²University of Sydney, Sydney, Australia

Contact address: Harri Hemilä, Department of Public Health, POB 20, University of Helsinki, Tukholmankatu 8 B 2B, Helsinki, FIN-00014, Finland. harri.hemila@helsinki.fi.

Editorial group: Cochrane Acute Respiratory Infections Group.

Publication status and date: New, published in Issue 9, 2017.

Citation: Hemilä H, Chalker E. Zinc for preventing and treating the common cold. *Cochrane Database of Systematic Reviews* 2017, Issue 9. Art. No.: CD012808. DOI: 10.1002/14651858.CD012808.

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effects of zinc to reduce the incidence, duration and severity of the common cold when used either as a daily supplement to prevent colds or as therapy at the onset of cold symptoms or during a cold.

BACKGROUND

Description of the condition

While familiar to most people, the ‘common cold’ is not a precisely defined disease (Eccles 2013). Typical cold symptoms include combinations of nasal symptoms, sore throat, cough and fever. The common cold is a significant cause of absenteeism from work and school.

The common cold is usually caused by one of a number of viruses. The respiratory viruses include rhino, corona, adeno, parainfluenza, influenza and respiratory syncytial types, which together have around 200 serotypes (Eccles 2009; Turner 2010). A number of non-respiratory viruses can also cause common cold-type symptoms. However, in a third of people with cold symptoms, the aetiology remains undefined even though extensive virological tests may be carried out. Similar symptoms can also be caused by mechanical irritation of the airways and from allergy or some bacterial infections. Hence, common cold symptoms do not always imply viral aetiology.

In common cold trials, symptom-based definitions of the common cold are almost always used. However, there is no explicit combination of symptoms and symptom duration that enables conclusions to be drawn about the aetiology. There is thus no rigorous definition of the common cold and the symptoms can vary substantially. It is the person’s subjective experience that prompts a visit to a physician to seek treatment or to ask for sick leave certification due to the common cold.

Most adults have one or two common cold episodes per year due to naturally occurring common colds. Laboratory studies have induced colds by inoculating high numbers of rhinovirus into the nose, which causes nearly all study volunteers to develop common cold symptoms within a few days.

Description of the intervention

Zinc is an essential nutrient for humans (Prasad 2013; Sandstead 2013). Zinc deficiency has been associated with increased susceptibility to infections (Prasad 2013). Zinc deficiency is quite common in low-income countries, but mild deficiency has also been observed in middle- and high-income countries (Prasad 2013). A

meta-analysis of six studies conducted in Bangladesh, India, Peru and South Africa concluded that zinc supplementation prevented pneumonia and that low dietary zinc levels may have practical importance in decreased resistance against infections (Lassi 2016). To treat zinc deficiency, or marginal deficiency, zinc has been administered as tablets and as a syrup (zinc supplements). For the treatment of the common cold, zinc has also been administered as lozenges soon after the onset of symptoms (Eby 1984). People with colds have been instructed to dissolve the lozenges slowly in the mouth several times per day. Nose gels and sprays have also been tested for treating the common cold. In the USA, the recommended daily intake of zinc is 11 mg/day for men and 8 mg/day for women (NRC 2001). However, zinc has been administered in doses of 100 mg to 150 mg per day to some people (not for the common cold) for several months with few adverse effects (Bamford 2012; Pories 1967; Serjeant 1970). Copper deficiency has been reported as a consequence of long-term zinc supplementation (Hoffman 1988; Prasad 1978), although a six-week experiment in which 150 mg/day of zinc was administered found no effect on plasma copper levels (Samman 1987). Due to the zinc and copper interaction, 150 mg/day of zinc is currently one of the standard treatments for Wilson's disease. Most people with Wilson's disease take 150 mg doses of zinc daily for life (Ala 2007; Marcellini 2005). In the treatment of Wilson's disease, zinc has an excellent safety profile, although it caused gastric irritation in 5% to 10% of people requiring therapy (Brewer 2005). The use of high-dose zinc for long periods in people with Wilson's disease indicates that zinc does not have long-term serious adverse effects, except for copper deficiency, which is reversible.

How the intervention might work

Zinc participates in the function of about 300 enzymes and has a range of effects on the immune system (Prasad 2008; Prasad 2013). For example, zinc has been reported to inhibit the replication of rhinovirus and respiratory syncytial virus (Geist 1987; Korant 1976; Suara 2004) and to enhance the effects of interferon (Berg 2001). However, the mechanism by which zinc supplements have an effect on pneumonia is not clearly understood (Lassi 2016). The major hypothesis in the use of zinc lozenges to treat the common cold is that the effect is due to local effects of free zinc ions in the oro-pharyngeal region (Eby 2010). However, the molecular-level mechanism of the effect of zinc lozenges for common cold treatment is not known. Although zinc might influence the local immune system, non-immune mechanisms have also been proposed to explain the effect of zinc lozenges on the common cold (Novick 1996; Novick 1997). The formulation of zinc lozenges appears to be critical (Eby 2010). Zinc binds effectively to citrate, and zinc lozenges containing citrate or citric acid do not release free zinc ions (Eby 1988; Eby 2010; Godfrey 1988; Martin 1988). Zinc acetate and zinc gluconate have been used as salts in zinc lozenges. Zinc acetate has been proposed as the better salt in zinc

lozenges because acetate binds to zinc ions very weakly, whereas gluconate binds the zinc ions more effectively. Given the stronger binding, zinc gluconate has been proposed as a less suitable constituent for zinc lozenges (Eby 2010). However, it is uncertain if variation in zinc ion binding leads to significant differences at the clinical level in the treatment of the common cold.

Why it is important to do this review

The common cold causes significant global morbidity, but identifying simple and effective preventive or therapeutic agents has been elusive. Even modest benefits for defined populations could be an important advantage from a public health perspective. In a survey of people with the common cold in the USA, about half had received antibiotics (Barnett 2014), although antibiotics are not usually of any benefit, since the common cold is caused mostly by viruses. Indiscriminate use of antibiotics can be harmful at both individual and population levels. Alternative treatment options such as zinc are therefore worth investigating.

Previous systematic reviews of zinc and the common cold have various shortcomings. Caruso 2007 used vote counting, that is counting the number of positive and negative studies, and had a number of other inadequacies (Hemilä 2013). Eby 2010 found dose-dependent effects of zinc lozenges on the common cold, but did not take into account variation in study size or calculate confidence intervals for the effect. Science 2012 combined zinc lozenge trials with zinc tablet and syrup trials, although zinc tablets and syrups were not intended to be dissolved in the oro-pharyngeal region, leading to the problem of combining 'apples with oranges' (Hemilä 2012). Since zinc tablets and syrups appear to have a different mechanism of effect to zinc lozenges, we will analyse them separately. A Cochrane Review on zinc and the common cold had a number of problems and was withdrawn (Hemilä 2015; Singh 2015). Given the issues with previous reviews, a thorough review is now warranted.

OBJECTIVES

To assess the effects of zinc to reduce the incidence, duration and severity of the common cold when used either as a daily supplement to prevent colds or as therapy at the onset of cold symptoms or during a cold.

METHODS

Criteria for considering studies for this review

Types of studies

We will include parallel-group randomised controlled trials (RCTs) including the first period of cross-over studies and cluster-RCTs if there are 10 or more clusters. We will include studies reported as full text, those published as abstracts only, and unpublished data. We will restrict our review to placebo-controlled trials. The common cold is a subjective experience, and there can be great variation among people in how they classify their symptoms and when they consider themselves to have recovered. However, as such subjective variation applies similarly to both intervention and placebo group participants, it should not lead to any bias. Subjectivity in the assessment of common cold symptoms can increase inaccuracy, which can lead to false-negative findings, but is unlikely to lead to false-positive findings in studies with adequate blinding.

Types of participants

We will include adults and children of either gender and any age. We will define children as people aged up to 18 years and adults as those aged 18 years and over. We will define older adults as those aged 65 years and over. We will not exclude studies with participants who have comorbidities.

We will include prevention trials that involved participants who did not have common cold symptoms before the intervention started.

We will include treatment trials that involved participants who had cold symptoms before the intervention started.

We will include studies in which participants had either natural common colds or induced common colds. We will analyse prevention trials and treatment trials data separately. We will also analyse natural common colds and induced common colds separately.

Types of interventions

We will include trials investigating oral zinc (tablets and syrups but not lozenges) versus placebo, zinc lozenges versus placebo, and nasal zinc administration versus placebo.

There will be no limitation on zinc dose administered by any route or duration of therapy.

We will not exclude studies with co-interventions.

Types of outcome measures

Because common cold is not a precisely defined disease, we will describe the definitions for the common cold applied in the included studies in 'Characteristics of included studies' tables in the review.

Primary outcomes

1. Incidence of colds during regular supplementation will be assessed as the proportion of participants experiencing one or more colds during the study period.

2. Duration of the common cold (i.e. time from cold onset to recovery).

3. Rate of recovery (i.e. how many participants recover on a given day) from the common cold.

4. Adverse effects (e.g. taste disturbances and stomach irritation).

Secondary outcomes

1. Severity of the common cold. Symptom severity is often measured on a scale, one scale for each symptom. The severity scores for each symptom are summed to provide a total severity score for a specific day. We will compare the average severity in the zinc groups with the average severity in the placebo groups.

2. Complications of the common cold (e.g. otitis, sinusitis, and exacerbation of asthma).

We will analyse measures of effect separately for prophylactic oral zinc (excluding lozenge) trials, prophylactic zinc lozenge trials, oral zinc (excluding lozenge) therapeutic trials, zinc lozenge therapeutic trials, and nasal zinc administration trials.

Search methods for identification of studies

Electronic searches

We will search the following databases from inception to present:

- Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Infection Group Specialised Register;
- PubMed; and
- Embase (Elsevier).

We will use the search strategy described in [Appendix 1](#) to search PubMed. We will modify this search appropriately for other databases and clinical trials registers.

We will also search ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (apps.who.int/trialsearch/).

Searching other resources

We will check reference lists of all primary studies and review articles for additional references. We will contact experts in the field to identify additional unpublished material.

Data collection and analysis

Selection of studies

Two review authors (HH, EC) will independently screen titles and abstracts identified as a result of the searches to select potentially eligible trials. We will retrieve the full-text study reports/publications, and two review authors (HH, EC) will independently screen the full texts and identify studies for inclusion, and identify and record reasons for exclusion of the ineligible studies. Any disagreements will be resolved through discussion. We will identify and exclude duplicates and collate multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (Moher 2009). We will include studies reported as full text, those published as abstract only, and unpublished data. We will not impose any language restrictions.

Data extraction and management

We will use a data collection form for study characteristics and outcome data that has been piloted on at least one study in the review. One review author (HH) will extract the following study characteristics from the included studies.

1. Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, diagnostic criteria, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of trial authors.

Two review authors (HH, EC) will independently extract outcome data from the included studies. We will note in the 'Characteristics of included studies' table if outcome data are not reported in a usable format. We will resolve disagreements by consensus. One review author (HH) will transfer data into the Review Manager 5 file (Review Manager 2014). Both review authors (HH, EC) will double check that data are entered correctly by comparing the data presented in the systematic review with those in the study reports, and they will check study characteristics against the trial reports and data collection forms for accuracy.

Assessment of risk of bias in included studies

Two review authors (HH, EC) will independently assess risk of bias for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

Any disagreements will be resolved by discussion. We will assess the risk of bias according to the following domains.

1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.

We will grade each potential source of bias as high, low, or unclear and provide a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We will summarise the 'Risk of bias' judgements across different studies for each of the domains listed. We will consider blinding separately for different key outcomes, where necessary. Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table.

When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome.

Assessment of bias in conducting the systematic review

We will conduct the review according to this published protocol and report any deviations from it in the 'Differences between protocol and review' section of the systematic review.

Measures of treatment effect

We will enter the outcome data for each study into the data tables in Review Manager 5 to calculate the treatment effects (Review Manager 2014).

We will calculate the risk ratio (RR) for dichotomous outcomes. We will calculate the effect of zinc on common cold duration in days, and we will calculate the pooled mean difference (MD) estimate. Because duration is a time-related outcome, we will also conduct survival analysis in accordance with guidance in Section 9.2.6 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). Survival analysis enables visual inspection and formal analysis of possible time-dependent variations in treatment effects. Survival analysis is not confounded by censored data or outlier participants who had particularly long colds. In contrast, outliers may decrease the statistical power of a t-test when examining cold duration, because these data inflate the standard deviation estimates.

Unit of analysis issues

If there are several zinc arms for a single placebo group, we will divide the placebo group for the zinc arms if we show several zinc arms in the same analysis table. If we find cross-over trials, we will include data for the first observation period. Because the common cold is contagious and different groups of people have different

levels of incidence, we will include cluster-randomised trials only if there are 10 or more clusters. In such cases, we will conduct the analysis at the same level as the allocation, using a summary measurement from each cluster.

Dealing with missing data

We will contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study is identified as abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of excluding such studies in the overall assessment of results by a sensitivity analysis. If numerical outcome data such as standard deviations or correlation coefficients are missing and cannot be obtained from the authors, we will calculate them from other available statistics such as P values according to the methods described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

Assessment of heterogeneity

We will use the I^2 statistic to estimate heterogeneity among the trials in each analysis. We will also use the χ^2 test to calculate the P value for the heterogeneity. We will consider an I^2 value of 50% or more to represent a substantial level of heterogeneity, though heterogeneity is not a dichotomous issue (Higgins 2003). If we identify substantial heterogeneity, we will report this and explore possible causes in prespecified subgroup analyses.

Assessment of reporting biases

We will construct funnel plots, but will interpret them cautiously, since there are a number of problems with the use of funnel plots in the assessment of publication bias (Ioannidis 2007; Lau 2006; Sterne 2011; Terrin 2005). We will also narratively consider the possibility of publication bias in the Discussion section.

Data synthesis

We will pool data from studies judged to be clinically homogeneous using Review Manager 5 software (Review Manager 2014). If more than one study provides usable data for any single comparison, we will perform fixed-effect meta-analysis.

GRADE and 'Summary of findings' table

We will create one 'Summary of findings' table with different sections for prophylactic oral zinc (not lozenge) trials, prophylactic zinc lozenge trials, oral zinc (not lozenge) therapeutic trials, zinc lozenge therapeutic trials, and nasal zinc administration trials. We will use the following outcomes: incidence and duration of the

common cold and adverse effects in zinc prophylactic trials; duration of the common cold and adverse effects in oral zinc therapeutic trials; duration of the common cold and adverse effects in nasal zinc therapeutic trials.

We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta-analyses for the prespecified outcomes (Atkins 2004). We will use methods and recommendations described in Section 8.5 and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), using GRADEpro GDT software (GRADEpro GDT 2015). We will justify all decisions to down- or upgrade the quality of studies using footnotes, and we will make comments to aid the reader's understanding of the review where necessary.

Subgroup analysis and investigation of heterogeneity

We plan to conduct subgroup analysis to investigate the preventive effects of zinc for people in low-income countries compared with those in middle- and high-income countries. We will use the World Bank 2017 classification to determine countries' income status. In the analysis of treatment effects, we intend to perform subgroup analyses for children, adults, and older adults where possible.

We will also explore the effects of zinc lozenges for:

1. dose of elemental zinc per day: < 75 mg versus \geq 75 mg; and
2. zinc acetate lozenges versus zinc gluconate lozenges in zinc lozenge trials with doses \geq 75 mg/day.

We will use the χ^2 test to test for subgroup interactions in Review Manager 5 (Review Manager 2014).

If there are several studies that are clinically so similar that they can be considered to measure the same effect, we may consider carrying out meta-regression to simultaneously analyse several subgroup variables. However, meta-regression is not a valid approach if there are fewer than 10 trials, as described in Section 9.6.4 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

Sensitivity analysis

We plan to perform sensitivity analyses excluding trials:

- with methodological shortcomings leading to inadequate randomisation or blinding; and
- those with missing data that required imputation.

ACKNOWLEDGEMENTS

The methods section of this protocol is based on a standard template developed by the Cochrane Airways Group and adapted by the Cochrane Acute Respiratory Infections Group. We wish

to thank the following people for commenting on the draft of this protocol: Ann Fonfa, Janet Wale, Craig Mellis, Martin Meremikwu, Teresa Neeman, and Paul Little.

REFERENCES

Additional references

Ala 2007

Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. *Lancet* 2007;**369**(9559):397–408.

Atkins 2004

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**(7454):1490.

Bamford 2012

Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP. Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. *International Journal of Dermatology* 2012;**51**(4):459–62.

Barnett 2014

Barnett ML, Linder JA. Antibiotic prescribing for adults with acute bronchitis in the United States, 1996–2010. *JAMA* 2014;**311**(19):2020–1. [DOI: 10.1001/jama.2013.286141; PUBMED: 24846041]

Berg 2001

Berg K, Bolt G, Andersen H, Owen TC. Zinc potentiates the antiviral action of human IFN- α tenfold. *Journal of Interferon and Cytokine Research* 2001;**21**(7):471–4.

Brewer 2005

Brewer GJ, Askari FK. Wilson's disease: clinical management and therapy. *Journal of Hepatology* 2005;**42** (Suppl 1):S13–21.

Caruso 2007

Caruso TJ, Prober CG, Gwaltney JM Jr. Treatment of naturally acquired common colds with zinc: a structured review. *Clinical Infectious Diseases* 2007;**45**(5):569–74.

Eby 1984

Eby GA, Davis DR, Halcomb WW. Reduction in duration of common cold by zinc gluconate lozenges in a double-blind study. *Antimicrobial Agents in Chemotherapy* 1984;**25** (1):20–4.

Eby 1988

Eby GA. Stability constants of zinc complexes affect common cold treatment results. *Antimicrobial Agents in Chemotherapy* 1988;**32**(4):606–7.

Eby 2010

Eby GA 3rd. Zinc lozenges as cure for the common cold - a review and hypothesis. *Medical Hypotheses* 2010;**74**(3): 482–92.

Eccles 2009

Eccles R, Weber R (editors). *Common Cold*. Basel: Birkhauser, 2009. [DOI: 10.1007/978-3-7643-9912-2]

Eccles 2013

Eccles R. Is the common cold a clinical entity or a cultural concept?. *Rhinology* 2013;**51**(1):3–8. [DOI: 10.4193/Rhino12.123; PUBMED: 23441305]

Geist 1987

Geist FC, Bateman JA, Hayden FG. In vitro activity of zinc salts against human rhinoviruses. *Antimicrobial Agents in Chemotherapy* 1987;**31**(4):622–4.

Godfrey 1988

Godfrey JC. Zinc for the common cold. *Antimicrobial Agents in Chemotherapy* 1988;**32**(4):605–6.

GRADEpro GDT 2015 [Computer program]

McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 12 July 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.

Hemilä 2012

Hemilä H. Zinc acetate lozenges may shorten common cold duration by up to 40%. hdl.handle.net/10138/40083 (accessed prior to 1 March 2017).

Hemilä 2013

Hemilä H. Zinc and the common cold: problems in the review by Caruso et al (2007). hdl.handle.net/10138/40817 (accessed prior to 1 March 2017).

Hemilä 2015

Hemilä H. Concerns about unattributed copying of text and data, and about numerous other problems in the Cochrane Review “Zinc for the common cold” by Singh M, Das RR (2013). hdl.handle.net/10138/153180 (accessed prior to 1 March 2017).

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ* 2003;**327**(7414):557–60. [DOI: 10.1136/bmj.327.7414.557; PUBMED: 12958120]

Higgins 2011

Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Hoffman 1988

Hoffman HN, Phylly RL, Fleming CR. Zinc-induced copper deficiency. *Gastroenterology* 1988;**94**(2):508–12.

Ioannidis 2007

Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. *CMAJ: Canadian Medical Association Journal*

- 2007;**176**(8):1091–6. [DOI: 10.1503/cmaj.060410; PUBMED: 17420491]
- Korant 1976**
Korant BD, Butterworth BE. Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides. *Journal of Virology* 1976;**18**(1):298–306.
- Lassi 2016**
Lassi ZS, Moin A, Bhutta ZA. Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months. *Cochrane Database of Systematic Reviews* 2016, Issue 12. [DOI: 10.1002/14651858.CD005978.pub3]
- Lau 2006**
Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. *BMJ* 2006;**333**(7568): 597–600. [DOI: 10.1136/bmj.333.7568.597; PUBMED: 16974018]
- Marcellini 2005**
Marcellini M, Di Ciommo V, Callea F, Devito R, Comparcola D, Sartorelli MR, et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. *Journal of Laboratory and Clinical Medicine* 2005;**145**(3):139–43.
- Martin 1988**
Martin RB. pH as a variable in free zinc ion concentration from zinc containing lozenges. *Antimicrobial Agents in Chemotherapy* 1988;**32**(4):608–9.
- Moher 2009**
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009;**339**: 2535.
- Novick 1996**
Novick SG, Godfrey JC, Godfrey NJ, Wilder HR. How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action. *Medical Hypotheses* 1996;**46**(3):295–302.
- Novick 1997**
Novick SG, Godfrey JC, Pollack RL, Wilder HR. Zinc-induced suppression of inflammation in the respiratory tract, caused by infection with human rhinovirus and other irritants. *Medical Hypotheses* 1997;**49**(4):347–57.
- NRC 2001**
National Research Council. Zinc. *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. Washington, DC: National Academies Press, 2001:442–501.
- Pories 1967**
Pories WJ, Henzel JH, Rob CG, Strain WH. Acceleration of wound healing in man with zinc sulphate given by mouth. *Lancet* 1967;**1**(7482):121–4.
- Prasad 1978**
Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P. Hypocupremia induced by zinc therapy in adults. *JAMA* 1978;**240**(20):2166–8.
- Prasad 2008**
Prasad AS. Zinc in human health: effect of zinc on immune cells. *Molecular Medicine* 2008;**14**(5-6):353–7.
- Prasad 2013**
Prasad AS. Discovery of human zinc deficiency: its impact on human health and disease. *Advances in Nutrition* 2013;**4**(2):176–90.
- Review Manager 2014 [Computer program]**
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- Samman 1987**
Samman S, Roberts DC. The effect of zinc supplements on plasma zinc and copper levels and the reported symptoms in healthy volunteers. *Medical Journal of Australia* 1987;**146**(5):246–9.
- Sandstead 2013**
Sandstead HH. Human zinc deficiency: discovery to initial translation. *Advances in Nutrition* 2013;**4**(1):76–81.
- Science 2012**
Science M, Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. *CMAJ : Canadian Medical Association Journal* 2012;**184**(10):E551–61.
- Serjeant 1970**
Serjeant GR, Galloway RE, Gueri MC. Oral zinc sulphate in sickle-cell ulcers. *Lancet* 1970;**2**(7679):891–2.
- Sterne 2011**
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;**343**:d4002. [DOI: 10.1136/bmj.d4002; PUBMED: 21784880]
- Suara 2004**
Suara RO, Crowe JE. Effect of zinc salts on respiratory syncytial virus replication. *Antimicrobial Agents in Chemotherapy* 2004;**48**(3):783–90.
- Terrin 2005**
Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. *Journal of Clinical Epidemiology* 2005;**58**(9):894–901. [DOI: 10.1016/j.jclinepi.2005.01.006; PUBMED: 16085192]
- Turner 2010**
Turner RB. The common cold. In: Mandell GL, Bennett JE, Dolin R editor(s). *Principles and Practice of Infectious Diseases*. 7th Edition. Vol. 1, Philadelphia: Churchill Livingstone, 2010:809–14.
- World Bank 2017**
World Bank. World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed prior to 12 July 2017).

References to other published versions of this review

Marshall 2000

Marshall I. Zinc for the common cold. *Cochrane Database of Systematic Reviews* 2000, Issue 2. [DOI: 10.1002/14651858.CD001364]

Marshall 2006

Marshall I. Zinc for the common cold. *Cochrane Database of Systematic Reviews* 2007, Issue 3. [DOI: 10.1002/14651858.CD001364.pub2]

Singh 2011

Singh M, Das RR. Zinc for the common cold. *Cochrane*

Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD001364.pub3]

Singh 2013

Singh M, Das RR. Zinc for the common cold. *Cochrane Database of Systematic Reviews* 2013, Issue 6. [DOI: 10.1002/14651858.CD001364.pub4]

Singh 2015

Singh M, Das RR. Zinc for the common cold. *Cochrane Database of Systematic Reviews* 2015, Issue 4. [DOI: 10.1002/14651858.CD001364.pub5]

* Indicates the major publication for the study

APPENDICES

Appendix I. MEDLINE search strategy

("Zinc Acetate"[Mesh] OR "Zinc Compounds"[Mesh] OR "Zinc"[Mesh] OR Zinc[tiab] OR Galzin[tiab] OR Zincteral[tiab])
AND

("Common Cold"[Mesh] OR "Rhinovirus"[Mesh] OR Cold[tiab] OR Colds[tiab] OR Rhinovirus[tiab] OR Rhinoviruses[tiab] OR Coryza[tiab] OR Catarrh[tiab] OR Catarrhs[tiab] OR "Respiratory infection"[tiab] OR "Respiratory infections"[tiab])

CONTRIBUTIONS OF AUTHORS

HH drafted the protocol and EC participated in its revisions. HH is the guarantor of the review.

DECLARATIONS OF INTEREST

Harri Hemilä: None known.

Elizabeth Chalker: None known.

SOURCES OF SUPPORT

Internal sources

- None, Other.

External sources

- None, Other.